Equities

EMIS Group PLC

EMIS Group PLC

Actions
  • Price (EUR)21.80
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+46.51%
  • Beta--
Data delayed at least 15 minutes, as of Dec 07 2022 19:34 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

EMIS Group PLC is a provider of healthcare software, information technology and related services in the United Kingdom. It operates through two segments: EMIS Health and EMIS Enterprise. EMIS Health segment is a supplier of integrated care technology to the National Health Service (NHS), including primary, community, acute and social care. Its EMIS Enterprise segment is focused on growth in the business-to-business (B2B) technology sector within the healthcare market, including management of medicines, partner businesses, life sciences and patient-facing services. The Company operates through its subsidiaries, which include Egton Medical Information Systems Limited, trading under the EMIS brand; Patient Platform Limited, carries on the business of Patient.info and Patient Access; and Pinnacle Systems Management Limited, is a provider of service management solutions to the community pharmacy market. Its clinical software business supplies essential technology to healthcare organization.

  • Revenue in GBP (TTM)171.99m
  • Net income in GBP28.22m
  • Incorporated2008
  • Employees1.51k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EMIS:LSE since
announced
Transaction
value
Fourteenfish LtdDeal completed17 Mar 202217 Mar 2022Deal completed49.60%--
Edenbridge Healthcare LtdDeal completed20 Jan 202220 Jan 2022Deal completed47.94%13.61m
Data delayed at least 20 minutes, as of Dec 07 2022 15:35 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.